美股A股
StockGist
Back
8-K2026-04-22· glm-5

INDP · Indaptus Therapeutics, Inc.

0001493152-26-018608

SEC filing

Summary

Indaptus Therapeutics appointed Tim Ruan and Dr. Yi Zhang as independent directors and accepted Matthew McMurdo's resignation, effective April 22, 2026.

Key takeaways

Full analysis

On April 17, 2026, the Board of Indaptus Therapeutics appointed Tim Ruan and Dr. Yi Zhang as independent directors, effective April 22, 2026. Mr. Ruan, currently CFO of Ocumension Therapeutics, brings financial and capital markets experience and was appointed to the Audit Committee, qualifying as an audit committee financial expert. Dr. Zhang, a Partner at JunHe, offers expertise in intellectual property and life sciences and was appointed to the Nominating Committee. Both directors enter under standard Independent Director Agreements providing a $30,000 annual retainer and Indemnification Agreements. Concurrently, Matthew McMurdo resigned from the Board on April 22, 2026, with no reported disagreements. The Board classified the new appointees as Class II directors with terms expiring at the 2026 annual stockholders meeting.